Purgo Biologics Inc. is a South Korean biomaterials company with over twenty years of dedicated expertise in the development and manufacturing of dental regenerative solutions, with particular emphasis on bone graft substitutes and barrier membranes.Anchored in its guiding principle, “Leading the New Standard of Regeneration,” the company pursues the advancement of clinically reliable and biologically optimised materials designed to support predictable regenerative outcomes in dental applications.Based on these clinical results, Purgo has published over 80 scientific papers, including SCI-level journals, and has proven product excellence through regulatory approvals in more than 50 countriesA recent nationwide survey conducted by the ‘Moreden’ professional dental community, involving 1,002 practitioners in South Korea, ranked Purgo as the Dentists’ No.1 Choice in Bone Grafts, reflecting strong practitioner confidence and widespread clinical adoption.THE Graft (porcine xenograft), the company’s flagship product, exhibits favorable clinical efficacy and is recognized for its superior biological performance. Building on this success, THE Graft Collagen (porcine xenograft with Collagen) achieved a significant regulatory milestone as the first in South Korea and the second worldwide in its category to be certified under the European Union Medical Device Regulation (EU MDR).This achievement underscores the robustness of Purgo’s translational research work and its unwavering commitment to the most stringent international standards in quality management and regulatory compliance.Purgo continues to strengthen its position as a leading global innovator in dental biomaterials through the expansion of a comprehensive product portfolio including advanced bone grafts, membranes and suture.